Abstract
Nasal NK/T-cell lymphoma is a rare subtype of lymphoma with a significantly worse prognosis than other subtypes, and also tends to be commonly found in people of East Asian, Mexican, or South American descent.
Patient 1 was treated with chemotherapy using the CHOP regimen after radiotherapy. At 14 months after the end of treatment the patient demonstrated recurrence to primary site and the jejunum. He is presently alive with this disease at 30 months after the end of treatment. Patient 2 was treated with chemotherapy using the CHOP regimen after radiotherapy, but this schedule resulted in only a partial response to the disease. As a result, chemotherapy was also performed using the DeVIC regimen with 3 cycles. Patient 2 is still alive and has been free of any relapse for 48 months. Patient 3 was treated with concurrent chemoradiotherapy using 56Gy irradiation with the DeVIC regimen. Patient 3 is still alive and has been free of relapse for 12 months. Because of this chemoradiotherapeutic regimen, patient 3 suffered severe mucositis and pancytopenia, and as a result he could not complete chemotherapy, which normally consists of 3 cycles. Patient 4 was treated with concurrent chemoradiotherapy using 56Gy irradiation with the DeVIC regimen. Patient 4 is still alive and has been free of relapse for 6 months. In patient 4, we used 2/3-dose chemotherapy in comparison to the patient 3 dose. As a result, the chemoradiotherapy in patient 4 did not cause any severe side effects. Concurrent chemoradiotherapy using the DeVIC regimen may therefore be effective for the treatment of NK/T-cell lymphoma.
